Takeda Pharmaceuticals (formerly Nycomed) 在哪里?
Takeda Pharmaceuticals (formerly Nycomed) 的总部位于 Zurich
Takeda Pharmaceuticals (formerly Nycomed) 的电话号码是多少?
Takeda Pharmaceuticals (formerly Nycomed) 的电话号码是 +41(800) 676-8975
Takeda Pharmaceuticals (formerly Nycomed) 的官方网站是什么?
Takeda Pharmaceuticals (formerly Nycomed) 的公司官方网站是
Takeda Pharmaceuticals (formerly Nycomed) 是做什么的?
Bem-vindo ao site corporativo da Takeda Brasil. Para informações específicas, visite o nosso site global.
Takeda Pharmaceuticals (formerly Nycomed) 的业务有哪些?
pharmaceuticals,life sciences,partnerships & licensing,emerging markets,specialty pharmaceuticals,respiratory,gastroenterology,inflammatory diseases,pain,osteoporosis,tissue management
Takeda Pharmaceuticals (formerly Nycomed) 的年收入是多少?
Takeda Pharmaceuticals (formerly Nycomed) 的收入是 0美元
Takeda Pharmaceuticals (formerly Nycomed) 有多少员工?
Takeda Pharmaceuticals (formerly Nycomed) 有 880 名员工
Takeda Pharmaceuticals (formerly Nycomed) 属于哪个行业?
Takeda Pharmaceuticals (formerly Nycomed) 从事以下行业: pharmaceuticals
Takeda Pharmaceuticals (formerly Nycomed) 使用什么技术?
Takeda Pharmaceuticals (formerly Nycomed) 使用的一些流行技术包括: ASP.NET,Bootstrap Framework,CloudFlare Hosting,EPiServer,Google Analytics,Google Tag Manager,JQuery 2.1.1,Microsoft Office 365,Mobile Friendly,Outlook,Route 53,Ruxit,YouTube
如何联系 Takeda Pharmaceuticals (formerly Nycomed)?
Takeda Pharmaceuticals (formerly Nycomed) 联系信息:
电话号码:+41(800) 676-8975,
网站:,
邮箱:gus***@***.com
Takeda Pharmaceuticals (formerly Nycomed) 的社交媒体链接是什么?
Takeda Pharmaceuticals (formerly Nycomed) 领英:http://www.linkedin.com/company/nycomed,fackbook:,twitte:https://twitter.com/TakedaPharma
Takeda Pharmaceuticals (formerly Nycomed) 是一家上市公司吗?
不是
Takeda Pharmaceuticals (formerly Nycomed) 的最后一轮融资是什么时候?
Takeda Pharmaceuticals (formerly Nycomed)在2018-06-01T00:00:00.000+00:00结束了最后一轮融资,金额达7.5B$。
谁投资 Takeda Pharmaceuticals (formerly Nycomed)?
Takeda Pharmaceuticals (formerly Nycomed) 有 2 家投资者,包括 J.P. Morgan Chase, Sumitomo Mitsui Banking Corporation, MUFG Bank, Mizuho Bank, Ltd、Bill & Melinda Gates Foundation。